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Abstract 
 
 Systemic Lupus Erythematosus (SLE) is a multifactorial and multisystemic chronic 
inflammatory autoimmune disease that occurs more frequently in women, particularly of 
childbearing age. Nearly half of SLE patients (56%) will experience depression and/or 
neuropsychiatric manifestations (NPSLE). These are major contributors to quality of life 
impairment, morbidity and mortality. Depression is one of the most common psychiatric 
complaints in SLE, affecting 17-75% of patients. Accordingly to the World Health 
Organization depression is a mental disorder characterized by persistent sadness, loss of 
interest, fatigue, suicidal thoughts and attempts. 
 
 The causes of depression remain largely unknown although genetic, biochemical 
and social factors appear to play an important role in its development. Particular attention 
has been given to the genes that encode proteins of serotonergic neurotransmission. 
Several polymorphisms in serotonin’s receptors and transporter have been associated 
with depressive symptoms in different settings. 
 
 This study aims to contribute to a better understanding of depressive states in SLE 
patients and their genetic determinants. For this purpose 96 SLE patients (91F, 5M; 39.7 
± 14.6 years) from the outpatient clinic of Clinical Immunology Unit of Hospital de Santo 
António – Centro Hospitalar do Porto were studied. Diagnosis of SLE was based in 
ACR1999 criteria. The Hospital Anxiety and Depression Scale (HADS) was used to 
characterize anxiety and depression, and the Short Form 36 (SF-36) test was used to 
evaluate quality of life. 38 patients were diagnosed with depression (HADS≥8) and 36 with 
neuropsychiatric SLE. Polymorphisms rs6314 and rs6313 of the 5-HTR2A (5-
hydroxytryptamine receptor 2a) gene and the STin-2 of the 5-HTT (5- hydroxytryptamine 
transporter) gene were genotyped by a Taqman assay, PCR-RFLP and PCR product 
sizing respectively. A group of 274 healthy individuals from the north of Portugal was used 
as control for the genetic studies. 
 
 Comparing SLE patients and controls no statistically significant differences were 
observed in genotypic and allelic frequencies of the polymorphisms studied. The 
frequencies of the rs6313T allele (57.1 vs. 41.3, p=0.041, OR [95%CI]=1.891 [1.02–3.49]) 
and rs6313TT genotype (31.4 vs. 9.60, p=0.027, OR [95%CI]=5.391 [1.22–23.82]) were 
higher in depressed SLE patients when compared to non-depressive SLE patients. No 
significant associations with the other polymorphisms were observed. These results 
suggest that SLE patients carrying the rs6313T allele are more prone to develop 
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depression. This polymorphism may alter the 5-HTR2A receptor expression or function 
leading to impaired serotonergic neurotransmission. To the best of our knowledge this is 
the first study to associate the 5-HTR2A rs6313 polymorphism with depression 
development on SLE patients, so replication studies are warranted. 
 
 Medico-legal concerns such as the prevention of suicide, or the consideration of 
the mental state of an accused in criminal trials, could also be impacted by these results. 
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Resumo 
 
 O Lúpus Eritematoso Sistémico (LES) é uma doença autoimune inflamatória, 
crónica, multifatorial e multisistémica com uma maior incidência em mulheres, em 
particular em idade fértil. Quase metade dos doentes com LES (56%) desenvolvem 
depressão e/ou manifestações neuropsiquiátricas (LESNP). Estas têm um papel 
importante na redução da qualidade de vida, na morbidade e na mortalidade. A 
depressão é um dos sintomas psiquiátricos mais comuns no LES e afeta cerca de 45% 
dos doentes com LES. De acordo com a Organização Mundial de Saúde a depressão é 
um transtorno mental caracterizado por uma tristeza persistente, perda de interesse, 
fadiga, pensamentos e tentativas de suicídio. 
 
 A causa da depressão permanece desconhecida embora fatores genéticos, 
bioquímicos e sociais possam desempenhar um papel importante no seu 
desenvolvimento. Particular atenção tem sido dada aos genes que codificam as proteínas 
reguladoras da neurotransmissão serotonérgica. Vários polimorfismos nos recetores e 
transportadores de serotonina têm sido associados a sintomas depressivos.  
 
 Este estudo pretende contribuir para uma melhor compreensão dos estados 
depressivos em doentes com LES e as suas determinantes genéticas. Para este efeito, 
foram estudados 96 doentes com LES (91F, 5M; 39,7 ± 14,6 anos) da Unidade de 
Imunologia Clínica do Hospital de Santo António – Centro Hospitalar do Porto. O 
diagnóstico de LES foi baseado nos critérios do ACR1999. O inquérito de saúde Hospital 
Anxiety and Depression Scale (HADS) foi utilizado para caracterizar a ansiedade e 
depressão e o teste Short Form 36 (SF-36) para avaliar a qualidade de vida. 38 doentes 
foram diagnosticados com depressão (HADS≥8) e 36 com LES neuropsiquiátrico. Os 
polimorfismos rs6314 e rs6313 do gene 5-HTR2A (5-hydroxytryptamine receptor 2a) e o 
STin2 do gene 5-HTT (5-hydroxytryptamine transporter) foram genotipados com 
tecnologia Taqman, PCR-RFLP e PCR com análise de fragmento, respetivamente. Um 
grupo de 274 indivíduos saudáveis do norte de Portugal foi usado como controlo no 
estudo genético. 
 
 Comparando os doentes com LES com os controlos não foi observada 
nenhuma diferença estatisticamente significativa nas frequências alélicas e genótipicas 
dos polimorfismos estudados. A frequência do alelo rs6313T (57.1 vs. 41.3, p=0.041, OR 
[95%IC]=1.891 [1.02–3.49]) e do genótipo rs6313TT (31.4 vs. 9.60, p=0.027, OR 
[95%IC]=5.391 [1.22–23.82]) eram mais elevadas em doentes com depressão quando 
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comparados com doentes sem depressão. Não foi detetada uma associação significativa 
com os outros polimorfismos estudados. 
 
 Os nossos resultados sugerem que doentes com LES portadores do alelo 
rs6313T estão mais propensos a desenvolver depressão. Este polimorfismo pode alterar 
a expressão ou função do recetor 5-HTR2A levando a uma transmissão serotonérgica 
anómala. Estudos de replicação são necessários para aprofundar o papel desse 
polimorfismo no desenvolvimento da depressão em doenças autoimunes, especialmente 
no LES.  
 
 Algumas implicações médico-legais como a prevenção do suicídio ou a 
consideração do estado mental de arguidos em processos penais também podem ser 
afetados por estes resultados.  
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1.1. Systemic lupus erythematosus  
 
 The immune system is a complex association of cells, tissues and organs and its 
main goal is protect the body from infectious organisms such as bacteria and virus. In SLE 
and other autoimmune diseases, the immune system loses its ability to distinguish 
between its own cells and foreign cells and tissues (antigens), thus the immune system 
develops autoantibodies directed against it (figure 1) (1). Autoimmune diseases’ incidence 
has been increasing around the world. Indeed, they affect about 5% of the European 
population with two thirds of the patients being female (2). 
 
 SLE is a chronic autoimmune disease that involves multiple organ systems such 
as skin, kidneys, lungs, 
blood and, in the most 
severe cases, the central 
nervous system (3). SLE 
pathogenesis remains 
unknown; however genetic 
factors are strongly 
correlated with SLE 
susceptibility. Environmental 
factors may also act as 
triggers for disease 
development (4). 
 
 
1.1.1. Epidemiology 
 
 SLE incidence and prevalence seems to be increasing. This may be due to the 
availability of better diagnostic tools and the increased identification of milder cases, 
adding to a proper increase of disease cases. In an USA population the incidence was 5.1 
per 100.000 per year and the prevalence was 52.2 per 100.000 and 3.8 and 26.2 in the 
United Kingdom (5). In the North of Portugal population the annual incidence rates of SLE 
is 2.3 cases per 100.000 persons (6). The male-to-female ratio is about 1:9 (4) and the 
female predominance is higher in women in the childbearing years compared to the 
Figure 1 – Normal immune response and autoimmune response. 
(Adapted:http://www.womensinternational.com/connections/autoim
mune.html. Accessed: 27.05.2015) 
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juvenile and elderly populations, probably due to the effect of female sex hormones on 
immune system (5). About 10%-20% of SLE cases manifest initially in childhood (before 
the age of 16 years) (7).  
 
 Mainly due to the immune system impairment, the body’s ability to prevent and 
fight infection is reduced, thus SLE patients have a superior risk for developing infection 
and complications (8). During the last 5 years of the Euro-Lupus project, arthritis and 
malar rash was the most prevalent manifestations and thrombosis was the most common 
cause of death (9). However the 10 year survival rate was 92%, a significant improvement 
when compared to 20th century (5). 
 
1.1.2. Etiology/Pathogenesis 
 
 The precise cellular and molecular mechanisms and which factors determine 
organ involvement is not clear (10). Disturbances in the immune system run with 
anomalies in cytokines, B-cell immunity and T-cell signaling, especially intense B cell 
activation (5). Indeed, Moulton et al characterizes the disease as an autoantibody 
production by dysregulated B cells (11). In addition, SLE is characterized by the 
production of a group of cytokines: the type 1 interferon (12), which in turn activates B and 
T cells (13). The disrupted immunological tolerance leads to a group of mechanisms 
associated with immune complexes deposition that are responsible for the manifestations 
of SLE (12). The therapy has relied on global immunosuppression, however it causes 
significant morbidity and mortality and side effects including infections and osteoporosis 
(14). 
 
 Although SLE is a complex disease with multifactoral etiology, it might be triggered 
by genetic and environmental factors such as microbial antigens, drugs and hormones. 
(13). 
 
1.1.2.1. Genetic factors 
 
 Multiple pathways predispose to the development of SLE. The disease has a 
strong genetic component and familial aggregation: the concordance of the disease was 
found to be 5.6% among first-degree relatives. The risk is also increased in siblings of 
SLE patients and in identical twins the concordance of the disease is approximately 25-
50% (15). In addition, around 10% to 15% of the patients have more than one affected 
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family members (16). The hereditary tendency strongly suggests that DNA polymorphisms 
influence the susceptibility to SLE. More than a hundred single genetic defects affecting 
the immune system cause SLE-like disease in mice (14). The most important genes 
associated with SLE are within the major histocompatibility complex (MHC). The function 
of MHC molecules is to bind peptide fragments derived from antigen and present them on 
the cell surface for recognition by the appropriate T cells. The human nomination of the 
MHC is the human leukocyte antigen (HLA). The HLA class II gene alleles HLA-
DRB1*15:01 and HLA-DRB1*03:01 have been associated with SLE susceptibility with a 
two to three fold increased frequency in patients compared to controls (17). 
 
1.1.2.2. Environmental factors 
 
 Recognized environmental factors trigger the disease in a genetically predisposed 
individual. Ultraviolet light and infections are implicated in the etiology. Ultraviolet light is 
the most well described environmental trigger in SLE. Due to sunlight exposure, skin 
disease can be exacerbated in those patients. On the other hand, the consequent 
avoidance of sunlight can lead to vitamin D deficiency. In fact, several studies show an 
inverse relationship between levels of vitamin D and disease activity (18).  
 
 Molecular mimicry between an infectious antigen and self-components is 
implicated as a pivotal mechanism by which SLE can be triggered. This phenomenon has 
been assumed to be a mechanism by which an invading organism evades the host 
immune response, as it is identified as “self”. On the other hand, due to the similar 
structure, these invading organisms can initiate an immune response in which both T-cells 
and B-cells cross-react with self-antigens (19). Infections caused by Epstein-Barr virus 
(EBV) have been reported as possible mediator in the development of SLE (20). A 
significant increase in EBV infection in pediatric lupus patients compared to controls was 
been described (21). In addition, the natural host cells of EBV are B cells which play a 
central role in SLE (22).  
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1.1.2.3. Hormonal factors 
 
 SLE is predominantly a female disease, as previously stated. The female 
predisposition declines with the ending of the reproductive age (15). Patients with 
Klinefelter’s syndrome, characterized by hypergonadotrophic hypogonadism, have an 
increased risk of SLE development (23). In patients with SLE of both genders an 
abnormal estrogen metabolism has also been described (24). A study with rodents 
demonstrate that administration of estrogen and prolactin can lead to autoimmune 
disease development (20). Another study with a cohort of 238.308 women followed up for 
27 years, revealed that early menarche, oral contraceptive use, early menopause and 
postmenopausal use of hormones were associated with an increased risk of SLE (25).  
 
 SLE also affects pregnancy: increased SLE activity at the conception time and the 
presence of damage associated with SLE before conception leads to complications in 
pregnant women, such as preterm birth and caesarean section. Thus, although the 
mechanism of action is unknown, the female hormones appear to be strong regulators of 
disease activity (5). 
 
1.1.3. Clinical Manifestations 
 
 SLE is a multisytemic disease and the manifestations vary widely (26). The 
constitutional symptoms include fatigue, fever and weight loss. Fatigue is the most 
common symptom in SLE patients probably due to the active disease, medications or 
lifestyle habits. Fever may also result from many causes such as SLE flare, infection and 
reactions to medications. The most common infections involve the respiratory tract, 
urinary tract and skin. In addition other opportunistic infections such as salmonella and 
herpes zoster may arise (8) (27). The severity of symptoms can range from mild 
cutaneous involvement to severe organ damage (4). 
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1.1.3.1. Dermatological manifestations 
 
 SLE was initially recognized as a dermatologic condition. The skin involvement 
occurs in up to 85% of SLE patients. There are three skin diagnostic criteria including 
malar rash, photosensitivity and discoid rash. The malar rash is characterized by an 
erythema over the cheeks and nasal bridge (figure 2). It is a butterfly-shaped that typically 
spares the nasolabial folds. In a group of SLE patients living in Dubai, malar rash was the 
commonest mucocutaneous manifestation (60,3%) (8). 
Photosensitivity is diagnosed when patients presents 
any unusual rash or symptom exacerbation after sun 
exposure. Exposure to ultraviolet light causes skin rash 
in face, arms or hands. Discoid skin rash is the most 
common form of chronic cutaneous lupus 
erythematosus. It is characterized by patchy redness 
that can cause scarring and also occurring in sun-
exposed areas. This manifestation can be a separate 
diagnostic entity (without organ involvement) or be part 
of SLE (27) (28). 
 
 
1.1.3.2. Musculoskeletal manifestations 
 
 Musculoskeletal symptoms are also reported in more than 90% of the patients 
(29), among which arthralgia and arthritis are present in 95% of patients (30). Indeed, joint 
pain is one of the most prevalent manifestations at presentation. In AlSaleh et al study, 
arthritis is even the most common clinical manifestation (8). Arthralgia and arthritis occur 
in the small joints of the hands, wrists, and knees although any joint is at risk. These 
symptoms may mislead, leading to the diagnosis of other types of inflammatory arthritis 
instead of SLE (27). 
 
 
 
 
 
Figure 2 – Malar rash. (Adapted:
http://www.nucleuscatalog.com/lup
us-erythematosus/view-
item?ItemID=9084. Accessed: 21-
06-2015) 
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1.1.3.3. Renal manifestations 
 
 Renal failure and infection are the two major causes of death in SLE patients. 
The kidney is the most affected visceral organ in SLE although only 50% of patients 
develop clinically evident renal disease. Additionally, biopsy studies showed that almost 
all patients with SLE present some degree of renal involvement. Clinical nephritis is 
mainly caused by deposits of immune complexes in the glomeruli. Acute or chronic renal 
failure may cause symptoms such as uremia and fluid overload. Acute nephritic disease 
can present with hypertension and hematuria. In addition, the glomerular disease that 
develops in the first years of the disease is usually asymptomatic (27). 
 
1.1.3.4. Neuropsychiatric manifestations 
 
 SLE can involve the central nervous system (CNS), leading to a wide spectrum of 
neuropsychiatric symptoms. Neuropsychiatric SLE (NPSLE) is one of the most important 
manifestations of SLE (31). Indeed, about half of SLE patients (56%) will have at least one 
NPSLE during the course of disease (32). These manifestations can occur at any time 
during the disease. Headache and mood disorders are described as the most common 
neurologic manifestations. The rate of depression is higher in SLE patients, particularly 
those with NPSLE, than in general population (33) (34). In fact it has been reported that 
17-75% of SLE patients have depression (34). On the other hand, the diagnosis of 
depressive symptoms is usually associated with other clinical manifestation and rarely 
with SLE. Nevertheless, the association between depressive symptoms and SLE has 
already been described for more than 100 years (35). 
 
 The cognitive functions include general intelligence, verbal learning/memory, 
visual–spatial skills, psychomotor speed/manual dexterity and attention/mental flexibility. It 
was reported that the majority of SLE patients present impairment in 3 or more domains 
(31). In addition, a study reported that NPSLE patients present poor performance on 
verbal and memory tests (36).  
 
 Delirium is one of the more uncommon NPSLE manifestations and its severity 
varies widely from mild confusion to profound disorganization with agitation and 
hallucinations (31). Likewise, psychotic events refer to paranoia with visual and auditory 
hallucinations in NPSLE patients (37). Furthermore SLE may precipitate epileptics status 
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and demyelinating disorders such as myelopathy and aseptic meningitis (27). 
Nonetheless, the diagnose is complex due to the difficulty of distinguishing psychological 
manifestations caused by SLE, by the burden of the disease (38), by concomitant drugs, 
infection or comorbidities.  
 
 The general symptoms of NPSLE are not specific however they are major 
contributors to impaired quality of life, morbidity and mortality (32). Ideally, patients with 
SLE should be assessed regularly for neuropsychiatric events and referral to psychology 
departments should be available (12). SLE is a chronic disease not only with physically 
impairment but it is also emotionally draining (32). 
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1.2. Depression 
 
 Depression is a common mental disorder, affecting approximately 121 million 
people worldwide. In Western Europe it affects between 10-55% of the population (39). 
According to the World Health Organization (WHO), depression manifests with depressed 
mood, loss of interest, low energy levels and fatigue; the person experiences feelings of 
guilt, thoughts of suicide and suicide attempts. It is still often associated with symptoms of 
anxiety and irritability. To be diagnosed depression should persist for a period, of at least, 
two weeks. These depressive symptoms are associated with a significant reduction in 
quality of life and functional capacity (40). WHO data report that in 2020 depression will be 
the second leading cause of disability throughout the world. Thereafter in 2030 it should 
become the main cause (41). In fact, even after successfully treatment, remission is rarely 
accompanied by a total loss of symptoms. Among them are cognitive and functional 
impairment, which affects quality of life. The burden of depression also influences the 
mortality risk (42). One particularly tragic consequence of depression is suicide. Almost 1 
million lives are lost each year, which translates into 3.000 deaths every day (43). 
 
 Depression can occur at any stage of a person's life (44). The disease affects 
both women and men, however women are more propense to be affected with the 
disease (45). In fact, it is the leading cause of disease-related disability in women. 
Epidemiological studies show that the prevalence of major depression is 21.3% and 
12.7% in women and men respectively (46). Biological factors are important in the several 
explanations for this fact. Hormonal factors, particularly at the onset of puberty, may 
account for the increased likelihood of women developing anxiety or depression (47). 
Furthermore, Hammen et al demonstrate that children with depressed mothers, have a 
higher predisposition to depression and social maladjustment (48). Depression in men is 
frequently undiagnosed and untreated. This is due to their difficulty to seek help since 
depression is often associated with powerlessness and the uncontrolled expression of 
emotion (49). Women had a greater propensity to commit suicide, although men 
presented a higher mortality rate in these circumstances (50). 
 Social factors have been recognized as essential for healthy aging and 
depression can arise due to lack of these factors. It was described that decreased social 
network and social support were related to depression in older people (51). Indeed, poor 
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social relationships is probably more injurious that drinking abuse (52). However the risk 
of developing depression is strongly biologically and genetically determined (53). 
 
1.2.1. Etiology 
 
 Psychiatric disorders have a complex etiology and it is crucial to consider that 
multiple causes contribute to a particular disorder. The etiology of depression differs 
widely from person to person; nonetheless there are risk factors that influence the 
development and the persistence of depressive episodes. Defining the factor/factors that 
trigger depression is quite important for, not only the treatment itself, but also for the 
patient to learn to avoid or deal with this factor. Biochemical, genetic and social factors will 
be discussed as well as the influence of illness and stress as factors that can lead to 
depression (54). 
 
1.2.1.1. Biochemical factors 
 
 The nervous system plays a role in the integration, coordination and 
communication between the different body parts of the human being. Neurons are the 
most important cells responsible for the transmission of 
nerve impulses. Through synapses, the neuron can pass an 
electrical or chemical signal to the next neuron. The chemical 
synaptic transmission uses chemical signals 
(neurotransmitters) released from presynaptic nerve 
terminals. Subsequently, the neurotransmitters bind to 
specific receptors on postsynaptic neurons completing the 
synapse (figure 3). There are several types of 
neurotransmitters but the main focus will be the biogenic 
amines. These include two large groups: cholines where 
acetylcholine is the main neurotransmitter and monoamines 
including serotonin, histamine and catecholamines 
(dopamine, epinephrine, norepinephrine) (figure 4) (55). 
 
 
Figure 3 – The general 
structure of a chemical 
synapse. (Adapted: Pereda,
A.E. 2014. Electrical 
synapses and their 
functional interactions with 
chemical synapses. Nat 
Rev Neurosci 15: 250-63) 
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1.2.1.1.1. Monoaminergic hypothesis of depression 
 
 Monoamines are neurotransmitters that contain one amino group connected to 
an aromatic ring by a two-carbon chain. The main monoaminergic systems in the CNS are 
histamine, dopamine, norepinephrine, epinephrine, serotonin and melatonin. For the 
development of major depression, the serotonergic, noradrenergic and dopaminergic 
systems are the most relevant (56). Disturbance of the metabolism of these monoamines 
and other neurotransmitters appears to play an important role in the development of 
depression and other neuropsychiatric disorders. Thus, the monoaminergic hypothesis 
states that depression is caused by a functional deficiency of monoamines particularly 
serotonin, dopamine and norepinephrine (57). The monoamine hypothesis was first 
formulated in the late 1960s. Currently, the monoaminergic system is considered the main 
system involved in the neurobiology of depression. Indeed, of several antidepressant 
drugs the mechanism of action increase serotonin levels in the synaptic cleft, supports this 
hypothesis (58). Another piece of evidence that supports the monoaminergic hypothesis is 
that patients with low levels of serotonin are more likely to committed suicide (59). 
 
 Phylogenetically, the serotonergic system is one of the oldest transmitter 
systems in the brain. Indeed, serotonin has an extensive system of innervations in most 
cortical and subcortical structures. Due to this diversity of signaling opportunities and 
functional roles this neurotransmitter has been associated with many different types of 
psychopathological conditions (60). Serotonin neurons use tryptophan to synthesized 
serotonin. The majority of intraneuronal serotonin is retained in storage vesicles and 
subsequently their release occurs by exocytosis. After release, the serotonin accumulates 
Figure 4 – Classes of neurotransmitters. 
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in the synaptic cleft. In order to control the amount of serotonin in the synaptic cleft there 
are specific transporter proteins that remove the neurotransmitter from the synapse (figure 
5). The remaining serotonin will connect to the receptors in the postsynaptic neuron (61). 
Fourteen different serotonin receptors have been identified. In fact they are grouped in 7 
distinct classes (5-HT(1) to 5-HT(7)) basis on their structural and operational 
characteristics (62).  
 
 Some authors refer the hypothesis that serotonin receptor 1A is involved in the 
pathophysiology of depression or depressive syndrome. In fact, in animal models of 
depression highly selective serotonin receptor 1A agonists possess antidepressant 
properties (63). Another serotonin receptor (HTR2A) has been implicated with depression. 
An increased density of this receptor in the brain of depressed individuals was described 
(64).  
 
 Indeed, monoamine depletion 
studies demonstrate that subjects with a 
family history of depression have decreased 
mood compared to healthy humans (65). 
However, depletion of a specific monoamine 
may be a too simplistic explanation due to its 
complex interactions. On the other hand, this 
probably helps to understand the vulnerability 
to become depressed (65). Therefore, several 
studies reported the urgent need for 
alternative hypotheses (66) (67). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Serotonergic system. MAO –
Monoamine Oxidase. COMT – catecol-o-
metiltransferase. (Adapted: http://visual-
science.com/projects/ssri/infographics/ 
Acessed: 27.05.2015) 
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1.2.1.1.2. Cytokine hypothesis of depression  
 
 Formulated by Smith in 1991, this theory explains the involvement of cytokines 
of the innate immune system in depression. This hypothesis postulated that depression is 
accompanied by immune deregulation. Activation of the immune system leads to 
increased secretion of proinflammatory cytokines. This is the only model of depression 
that can bridge the diagnostic gap between physical and mental disorders (68). Cytokines 
are chemical messengers used by cells of the immune system to communicate with one 
another. Once in the blood, cytokines can alter the function of every tissue and organ, 
including the brain. In addition, they are also responsible for physical signs such as 
inflammation, headache, depressed mood, hormonal and biochemical abnormalities.  
 
 Depressed patients have activated immune systems and secrete more cytokines 
than normal controls. In addition, the most severely depressed patients have the most 
activated immune systems (69). Furthermore, cytokines have powerful effects on 
neurotransmitters including serotonin, dopamine and norepinephrine. Thus, cytokines can 
be an explanation for the neurotransmitter abnormalities found with psychiatric diseases 
(69) (70).  
 
 There are several types of cytokines, for example interleukins (IL-1, IL-2, IL-6), 
interferon (IFN-γ) and tumor necrosis factor (TNF-α). Dowlati et al reported significantly 
higher concentrations of proinflammatory cytokines TNF-α and IL-6 in depressive patients 
compared to psychiatrically healthy subjects (68). Accordingly, the administration of 
inflammatory cytokines can induce an increased indoleamine-2,3-dioxygenase (IDO) 
activity. This enzyme catalyzes the first step of essential aminoacid tryptophan 
degradation to N-formyl-kynurenine influencing negatively the synthesis of serotonin. 
Consequently, this leads to the appearance of depressive symptoms due to IDO activity 
pushing tryptophan away from the serotonin pathway and into the kynurenine pathway, 
leading to an increase of kynurenic acid and quinolinic acid concentrations that are also 
correlated with depressive behaviors (figure 6) (71) (72).  
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 A study described increased 
rates of depression induced by 
lipopolysaccharide administration in 
healthy male volunteers, suggesting 
that cytokines are involved in the 
etiology and symptomatology of 
illness-associated depression (73). 
Thus interaction between pre-existing 
vulnerabilities and inflammatory 
stimuli may act as a trigger in 
depression development (74). The 
ability of cytokines to modulate 
hippocampal neurogenesis (the 
generation of new neurons) has also 
been reported (75). This subject will 
be focus in the next topic. 
 
1.2.1.1.3. Neurogenic hypothesis 
 
 Newborn neurons are continuously added to the adult hippocampus. Researchers 
were focused on the hippocampus since it is also an area of the brain important for stress 
regulation, cognition and mood. First formally proposed in 2000, the neurogenic 
hypothesis claims that depression is at least partially caused by an impairment of the 
brain's ability to produce new neurons (58). 
 
 The neurogenic hypothesis was formulated based on several observations. For 
instance, evidences from post-mortem and imaging studies reported a significantly lower 
hippocampal volume in subjects with major depression (76) (77). Their hippocampi also 
appear to be smaller during periods of depression when compared to periods of 
remission. Consequently, decreased hippocampal neurogenesis was claimed. In addition, 
the authors suggest that this decrease leads to a reduced monoaminergic 
neurotransmission; which in turn promotes an altered activity of emotion and cognition 
(77) (78). Corroborating to this hypothesis, the chronic administration of antidepressants 
that raises the levels of serotonin, leads to an increase adult hippocampal neurogenesis in 
stressed rodents and primates (58). 
 
Figure 6 – Serotonin pathway and kynurenine pathway 
from L-tryptophan metabolism. (Adapted:
https://neuroendoimmune.wordpress.com/. Accessed: 
03-02-2014) 
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 According to this hypothesis it may be possible to predict risk factors based on 
factors that decrease neurogenesis. 
 
1.2.1.2. Genetic factors  
 
 Genetic factors play an important role in the development of depression. Twin 
studies suggest a heritability of 40-50%. Also family studies reported a twofold to threefold 
increase in lifetime risk of developing depression among first-degree relatives (79). Many 
genetic association studies have been conducted since the first case–control study on the 
relationship between polymorphisms and depression (80). Since they are candidate 
genes, greater attention has been given to the serotonergic receptor and transporter 
genes. to the susceptibility of mental disorders (81). Additionally, the genes encoding the 
catecholamines enzymes degradation monoamine oxidase A (MAO-A) and catechol-O-
methyl-transferase (COMT) will be analyzed (82). 
 
1.2.1.2.1. Serotonin Receptor 2A 
 
 The 5-HTR2A (5-hydroxytryptamine receptor 2A) is responsible for the 
regulation of anxiety, mood, memory and cognition. It is also the target of several 
antidepressant drugs (83). This receptor is encoded by the 5-HTR2A gene located on 
chromosome 13 (13q14-21) (84). 
 
 It has been showed that the polymorphism rs6313 (102T>C) may interfere with 
5-HTR2A mediated neurotransmission. In a sample of 485 European descendent patients 
with major depression, the C allele of this single nucleotide polymorphism (SNP) was 
more frequent in depressed patients. It was also associated with a more severe major 
depressive episode (85). However, in other populations no evidence of genetic 
association of rs6313 with depression was found (86). Additionally it was reported that 
rs6313 is associated with suicide attempts in female alcoholic patients (87). This 
polymorphism was been predominantly analyzed in association with personality traits. 
One study described the association in Italian mood disorder patients (88). 
 
 Another polymorphism, rs6314 (1345C>T) has been reported to decrease the 
receptor`s intracellular signaling (89). The SNP has been shown to be associated with 
depression symptoms severity and response to antidepressants in adults with diagnosed 
depressive disorder. Nevertheless results are not consistent. The rare TT variant of 
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rs6314 was reported in two patients with severe melancholic major depression (85). On 
the other hand, there was no significant association between rs6314 with severity of 
depression symptoms in children with autism spectrum disorder (90). Moreover, a study 
with 166 European descendent patients receiving paroxetine for major depression 
treatment demonstrated that the rs6314 heterozygote’s individuals had a better response 
to this antidepressant (91).  
 
1.2.1.2.2. Serotonin Transporter 
 
 Candidate gene studies also involve the serotonin transporter (5-HTT) gene in a 
wide range of neuropsychiatric disorders such as depression and bipolar disorder. The 5-
HTT is encoded by the serotonin transporter gene SLC6A4, located on chromosome 17 
(17q11.1-17q12) (92) (93). A VNTR (STin2) polymorphism located in the intronic region 
has been implicated in the regulation of transcription levels (94). The STin2 polymorphism 
consists of three alleles: STin2.9; STin2.10 and STin2.12 repeat units of 17bp. Some 
reports described that STin2, in particular the 12 repeats allele, is associated with higher 
transcriptional levels. This leads to a superior number of receptors and consequently to 
lower serotonin availability (92) (95). Thus, impairment in serotonin metabolism, may in 
part underpin the development of depressive symptoms. 
 
 The STin2.12 allele is positively associated with comorbid tobacco use disorder 
and mood disorders such as depression or bipolar depression (96). Another study 
described that patients with STin2 9/12 or 12/12 genotype had fourfold higher odds of post 
stroke depression when compared to STin2 10/10 genotype carriers (97). 
 
 An additional polymorphism in the serotonin transporter was described. A 44 bp 
repeat polymorphism in the promoter region of the gene (5-HTTLPR) has been shown to 
influence expression levels of the serotonin transporter in vitro (79). It consists in a 44 bp 
insertion (long allele “L”) or deletion (short allele “S”). The S allele has been reported to be 
associated with lower level of transcriptional efficiency of the 5-HTT in membranes. 
Therefore, this allele is considered to be less efficient than L allele (98). Likewise, 
Bonvicini et al referred in their study that, in human post-mortem brains, the L allele is 
associated with higher transcriptional activity. Consequently the rate of serotonin reuptake 
is higher (95). Recent studies show that depressed individuals usually have a higher 
frequency of S alleles compared to non-depressed controls. In addition, S allele has been 
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associated with suicide (99) and several mood disorders like neuroticism and anxiety 
symptoms (100).  
 
 A rs25531 SNP in the serotonin 
transporter SLC6A4 gene is the nearest 
polymorphism of 5-HTTLPR (101). It is 
located immediately outside of the 5-HTTLPR 
segment resulting in a strong link between 
them (figure 7). Due to their proximity, the 
rs25531 SNP appears to modulate the effect 
of the 5-HTTLPR on transcriptional efficacy 
(102). The rs25531 (25531A>G) can be 
found in the context of L and S alleles of 5-
HTTLPR. The G allele occurring frequently 
with L allele diminished the transcription 
levels when compared to A allele (103). This 
fact is relevant to neuropsychiatric disorders 
due to the association of the SNP with 
differences in emotional and personality 
characteristics (104). Additionally, a study 
with 97 healthy individuals concluded that 
homozygote individuals for the G allele may 
have a tendency to be more optimists and 
more resilient to stress than individuals 
carrying an rs25531 A allele (105). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Human SLC6A4 gene organization. 
(Adapted: Murphy DL, Moya PR. 2011. Human 
Serotonin Transporter Gene (SLC6A4) 
Variants: Their Contributions to Understanding 
Pharmacogenomic and Other Functional G x 
G and G x E Differences in Health and 
Disease. Current opinion in pharmacology 11: 
3-10) 
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1.2.1.2.3. Monoamine degradation enzymes 
 
 One of the most frequently investigated genes, in major depression studies, is the 
COMT gene located on chromosome 22q11. The COMT gene codes for one of the 
principal enzymes involved in catecholamine degradation and a key modulator of 
dopamine levels in the human brain (106). Functionally, this enzyme is responsible for 
removing monoamines from the synaptic cleft in the prefrontal cortex due to the absence 
of a specific transporter in this region (107). Genetic variation in the COMT gene has been 
associated with a 40% increase in enzyme activity. Analyses of human post-mortem 
dorsolateral prefrontal cortex support the hypothesis that higher enzyme activity results in 
lower dopamine bioavailability (107). Consequently, it leads to an impaired dopamine 
neurotransmission and an increased risk for major depression development (108). 
 
 Another important enzyme is MAOA. The MAOA gene maps to the short arm of 
the X chromosome (Xp11) and codes for a mitochondrial outer membrane enzyme 
involved in the degradation of neurotransmitters such as serotonin, norepinephrine and 
dopamine. Human and animal research has supported the involvement of MAOA gene in 
mood disorders and in aggressive behavior. Genetic variations in MAOA gene cause 
different transcriptional activities that result in different expression levels of this gene 
(109). The variation that has been most studied consists of a 30 bp VNTR with 2, 3, 3.5, 4 
and 5 repeats. Functional studies revealed that this alleles displayed differential 
expression. The 3 repeat allele presents lower transcription efficiency than the alleles with 
3.5 or 4 repeat that transcribed 2–10 times more efficiently. Indeed, it has been shown an 
association between the 3 repeated allele and neuropsychiatric conditions, antisocial 
personality and poor reaction to stress. Higher gene expression has been associated with 
suicide caused by depression (110). In addition, in a study with 42 post-mortem human 
brain, a higher level of MAOA was found in the hypothalamic region (111). 
 
 Another association study indicated that low activity of both enzymes MAOA and 
COMT, appears to influence mood during stressful events, in particular the peripartum 
period (112). 
 
 
 
 
 
Chapter 1 - Introduction 
ICBAS - UP 
 
19 
 
 
1.2.1.3. Stress  
 
 Stress is a factor implicated in psychiatric disorders. It is well established that 
stressful life events are associated with risk for depression. When compared to those 
without vulnerability, depression-prone individuals are active agents in the creation of prior 
stressful life events, particularly major undesirable events (113). Continuing negative 
environmental circumstances (chronic stress) such as poor working conditions, financial 
difficulties, conflicting intimate relationships with romantic partners, parents, children, or 
friends; continuing health problems and other ongoing burdens are included (114). Their 
responses are inappropriate and may result in adverse mental and psychological effects 
such as anxiety, panic disorders and depression. Indeed, when the stress situation occurs 
over a period of time, the depression may arise insidiously covered by continued 
symptoms of anxiety, the so called “masked depression” (115). 
 
 Glucocorticoids like cortisol, that is released in response to stress, appears to be 
increased in depression. This is due to the changes in the endocrine and immune systems 
that are associated with the disorder but also with changes in central neurotransmitter 
function. Stress is regularly 
associated with activation of a 
specific neuroendocrine pathway, 
the hypothalamic–pituitary–adrenal 
(HPA) axis. Initially, stress stimulates 
the hypothalamus to release the 
corticotrophin-releasing hormone 
(CRH). This hormone influences the 
pituitary to stimulate the secretion of 
adrenocorticotropic hormone (ACTH) 
that in turn culminates in the release 
of glucocorticoids from the adrenal 
gland (mainly cortisol in humans). 
Glucocorticoids in turn act back on 
the hypothalamus and pituitary to 
suppress CRH and ACTH production 
in a negative feedback cycle (figure 
8) (116).  
Figure 8 – The stress response mediated by the 
hypothalamic–pituitary–adrenal (HPA) axis. CRH: 
Corticotropin releasing hormone; ACTH: 
adrenocorticotropic hormone. (Adapted: Stephens MA, 
Wand G. 2012. Stress and the HPA axis: role of 
glucocorticoids in alcohol dependence. Alcohol Res 
34: 468-83) 
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1.2.1.3.1. Dysfunction of the HPA axis 
 
 Dysfunction of the HPA axis presents a challenging hypothesis in the neurobiology 
of depression. It has been shown that the inhibitory feedback mechanism, that normally 
reduces the activity of the HPA axis, is largely insensitive to the effect of raised 
glucocorticoids in depressed patients. The chronic raised glucocorticoid levels in major 
depression are associated with activation of macrophage activity. It is already established 
that both, infections and active autoimmune inflammatory processes are associated with 
activation of the HPA axis. Indeed, cytokines particularly those produced by macrophages 
are mediators of inflammation. Of these mediators, the pro-inflammatory cytokines TNF-α, 
IL-1 and IL-6 appears to play an importance role in the activation of the HPA axis. The 
activation mediated by these cytokines is greater than the one observed with maximal 
stimulatory doses of CRH. This suggests that the hypothalamus and other stimulators of 
ACTH release are also activated by these cytokines (117).  
 
 The continuing hyper secretion of glucocorticoids has implications in the normal 
functioning of the brain and the immune system. The long-term consequence of these 
endocrine and immune changes leads to increased morbidity in depressed patients. 
 
1.2.1.4. Illness 
 
 People affected with some illness, can present mood changes and reduced 
physical capacity in a way that possibly leads to depression. Depression must occur after 
the onset of the disease to be considered a direct result of medical condition. In addition, 
a plausible mechanism connecting depression and the medical condition should exist 
(118).  
 
 Certain illnesses like Parkinson's disease strikingly increase the chance of 
developing depression however, little is known about its pathological mechanisms (119). 
Cancer patients have psychiatric comorbidities and the stage of cancer is associated with 
depression or anxiety. In fact, a study in a Tertiary General Hospital in Singapore refers a 
higher prevalence of depression in those with terminal cancer. That could be related to 
pain and physical disability (120) although some studies have reveal a possible 
association between cancer stage and depression (121) (122). Yoshida et al explain that 
blood glucose is a strong regulator for mood states in patients with diabetes. These 
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patients have a poor glycemic control that can induce negative feelings (123). A 
Portuguese study of multiple sclerosis patients also supports a close linkage between 
depression and physical disability (124). In addition, it has been estimated that people 
with type 2 diabetes mellitus are twice as likely compared to the general population to 
suffer from depression (125).  
 
 The high prevalence of depression in patients with inflammatory diseases is a 
strong evidence of the effect of cytokines in depression. Patients receiving chronic therapy 
with IFN-α have high prevalence of depressive symptoms (20-50%) (126) (127). Likewise, 
neuropsychiatric events such as mood disorders and major depressive episodes have a 
frequent occurrence in patients with SLE (128). Increased SLE disease activity appears to 
be associated with an increased vulnerability for depressive disorders (35). Accordingly, a 
Chinese study with a total of 285 SLE patients, reported that 34.4% of SLE patients had 
current suicidal ideation (129).  
 
 It was described that SLE patients with brain lesions in areas of the limbic system, 
presented an impairment in emotional and behavioral functions (34). Neuroanatomical 
changes may also play an important role in depression symptoms. Indeed, depressed 
individuals have a lower cerebral blood flow compared with age-matched healthy control 
subjects (130). This was also observed in depressive SLE patients (118). Moreover, the 
loss of cerebral and cerebellum volume is a clinical feature of NPSLE in children and 
adolescents (131). 
 
 Depressive symptoms can be associated with physical limitations or with patient’s 
response to the burden of disease (34). Some authors consider depression an example of 
the silent burden of the disease (32). The multiple factors that contribute to increase the 
overall vulnerability for depression is summarized in figure 9. 
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1.2.2. Types of depression 
 
 It is important to taken into account the division of depressive disorders in their 
subtypes in order to the most appropriate treatment. There are different forms of 
depressive disorders; major depressive and dysthymic disorder are among the most 
common. The following division is based on the Diagnostic and Statistical Manual of 
Mental Disorders 5th edition (DSM–V): 
 
• Mood changes are characterized by serious explosions with an abnormal 
intensity or duration patterns, manifested both verbally and behaviorally; 
 
• Major depression when depressive symptoms persist for at least two weeks; 
 
• Dysthymia is diagnosed when manifestation are prevail for two or more years; 
 
• In premenstrual dysphoric disorder, the symptoms occur in the week before the 
onset of menses and improves days after the beginning of the same; 
 
Figure 9 – Diagram of the etiology of depressive symptoms. (Adapted: Sperner-Unterweger B, 
Kohl C, Fuchs D. 2014. Immune changes and neurotransmitters: possible interactions in 
depression? Prog Neuropsychopharmacol Biol Psychiatry 48: 268-76) 
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• Substance/medication induced depression is a prominent and persistent 
disturbance of mood that prevails in the clinical perspective. Alcohol, cocaine, 
anxiolytics or amphetamine stimulants are examples of substances implicated in 
this disorder; 
 
• Depressive disorder associated with another medical condition requires 
confirmation from a physical examination or laboratory findings, to prove the 
disturbance is a direct result of another illness; 
 
• Specific depressive disorder is a diagnosis applied to cases where the 
symptoms do not meet the criteria mentioned in the above disorders; 
 
• Non-specific depressive disorder is diagnosed in situations where the physician 
chooses not to specify any cause (45) (132). 
 
1.2.3. Treatment 
 
 There are several well documented treatments for depression. These include 
many drugs, psychotherapeutic intervention and electroconvulsive therapy; the first two 
are the most particularly used (133). 
 
1.2.3.1. Psychotherapeutic treatment 
 
 The reasons regarding the choice of psychotherapy instead of pharmacotherapy 
for the treatment of depression are not well understood. Nevertheless, the choice of a 
psychotherapy reduces the probability of treatment failure, regardless of the number of 
sessions. There are some types of psychotherapeutic interventions, classified according 
to their theoretical basis: 
 
• Cognitive behavioural therapy (CBT); 
 
• Interpersonal psychotherapy (IPT); 
 
• Counselling. 
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 CBT is the most studied therapy for the treatment of depression. The goal is to 
correct the behavioral functions, showing to patients that their thinking affects their mood. 
It is based on the understanding that thinking negatively is a habit that keeps depressive 
symptoms (134). Chen H. et al demonstrated that CBT effectively reduce the symptoms of 
depression in a group of women with an initial episode of moderate depression. 
Furthermore, this therapy has also shown efficacy in the treatment of sleep disorders 
(135). 
 
 The IPT is based in social roles and life events. This treatment is based on the 
fact that depression and interpersonal problems are interrelated. Actually, both CBT and 
IPT have been found to be efficacious for treating depression (136).  
 
 Such interventions are particularly useful in slightly adverse situations. Indeed, 
the role of psychotherapy in the treatment of depression has been subject to some 
doubts. With the emergence of new drugs, the proportion of people subject to 
psychotherapy has been declining (137). 
 
 Another study indicates that less intensive interventions improve clinical 
outcomes of antidepressant treatment. Counseling, in the form of telephone contact by 
nurses, also increased patient satisfaction. This study included patients who 
simultaneously started a drug treatment and the referred emotional support. The latter has 
been focused on the realization of about twelve to fourteen calls, approximately ten 
minutes each for four months. In these phone calls questions about taking the 
antidepressant were emphasized, as well as the identification of activities that could make 
a person more active and that allowed them to find pleasure in their execution (138). 
 
1.2.3.2. Pharmacotherapeutic treatment 
  
 A large number of studies show that antidepressants are effective and are the 
mainstay of treatment for serious and chronic depression. Treatment goal should be the 
complete remission of symptoms and not just partial improvement. Thus, for about one 
third of patients the first choice treatment is indifferent; that is due to the response and/or 
toleration to medication. Indeed, recent studies indicate that only 30-40% of patients 
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respond optimally to one pharmacotherapeutic treatment. The remaining 60-70% of 
patients do not have the same favorable response (139). 
 
 With scientific development these drugs are increasingly effective in control and 
treatment of depression. Particularly, drugs interfere with the action of neurotransmitters 
such as serotonin and norepinephrine. Indeed, the older drugs affect these 
neurotransmitters: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors 
(SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs) and also 
monoamine oxidase inhibitors (MAOIs). All of these are effective by increasing the 
availability of monoamines (140). 
 
 The first generation of antidepressants, where TCAs and MAOIs are included, 
showed effectiveness, despite some side effects. The second generation of 
antidepressants, include SSRIs, are selective noradrenaline reuptake inhibitors (NRIs), 
selective inhibitors of the reuptake of norepinephrine-dopamine (NDRIs) and SNRIs with 
improved side effects and improved tolerance. However there are no advances regarding 
the most important target. In fact, one of the oldest TCA (clomipramine) remains among 
the most effective antidepressants (141) (142). This is mainly due to the existence of a 
significant period of time between the beginning of the treatment and the manifestation of 
the beneficial effects (143) (144). 
 
 After remission, treatment should be continued for at least six months since the 
risk of relapse is high if the duration of treatment is shorter. However the level of 
effectiveness and tolerance of antidepressant varies from person to person (145). 
 
1.2.3.3. Sports as therapy 
 
 As an adjunct to conventional therapies, the role of physical exercise has been 
the subject of several studies. The therapy has demonstrated its effectiveness in reducing 
the symptoms of depression (146) (147) (148). Actually, some of these studies have 
reported that exercise can have equivalent efficacy to the use of pharmacological 
treatments (149) (150) (151) or psychological interventions (152). Stanton et al described 
that aerobic exercise performed three or four times per week showed a positive effect in 
the treatment of depression. It was execute in moderate programs of 30-40 minutes, 
carried for a minimum period of nine weeks. Mainly, the exercise program that is effective 
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for the treatment of depression is not substantially different the one recommended for the 
general population (153). 
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Aims 
 
 SLE is not only a physically impairing chronic disease, but also emotionally 
draining. SLE is also associated with central nervous system involvement, leading to a 
wide spectrum of neurological symptoms and varied psychiatric manifestations. The 
disease can have a severe impact on individual quality of life and present serious 
obstacles to life goals achievement in young individuals. Recognition of depression in SLE 
patients is of extreme importance since it is treatable, and can lead to fatal consequences 
if unrecognised. Further exploration of genetic susceptibility factors for depression in SLE 
will help to improve patient management and treatment, as well as in prevention 
strategies. 
 
 This study was conducted to: 
 
• Determine if serotonergic system molecules are implicated in 
the development of depressive symptoms in SLE patients. To this end 
the polymorphisms rs6313 and rs6314 of the 5-HTR2A gene, and the 5’ 
VNTR of the 5HHT gene were studied; 
 
• To evaluate the putative association of the polymorphisms 
studied with SLE susceptibility. 
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3.1. Materials 
 
3.1.1. Study population 
 
 This study included 96 patients (91 females and 5 males, age= 39.7±14.6 
years) with SLE from the outpatient clinic of the Clinical Immunology Unit of Hospital de 
Santo António – Centro Hospitalar do Porto. The control population was composed of 274 
healthy individuals without physical and psychological diseases, from the same 
geografical region.  
 
 The diagnosis of SLE was made according to the criteria established by the 
American College of Reumathology (ACR). Patients were referred to neurology clinic 
where were diagnosed with or without involvement of the central nervous system (NPSLE 
and without NPSLE) using the ACR criteria (1999) and the doctor's clinical experience. 
 
 Surveys such as the Short Form 36 (SF-36) and the Hospital Anxiety and 
Depression Scale (HADS) were also applied. The first is a general health-based survey of 
quality of life. The SF-36 includes one multi-item scale that explores eight health 
concepts: 1) limitations in physical activities because of health problems; 2) limitations in 
social activities because of physical or emotional problems; 3) limitations in usual role 
activities because of physical health problems; 4) bodily pain; 5) general mental health 
(psychological distress and well-being); 6) limitations in usual role activities because of 
emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. 
SF-36 was composed by 36 items with several responses choices. Each item is scored on 
a 0 to 100 range and a high score defines a more favorable health state (154). The HADS 
is used as a screening the existence of elevated levels of anxiety and depressed mood, 
allowing an evaluation of the emotional state of the patient. This inquiry is made up of a 
set of seven questions with four possible answers, scored from 0 to 3. The final scores are 
between 0 and 21 points. With score of 0 to 7 could be considered in the normal range, a 
score of 8 to 10 being just suggestive of the presence of depressive symptoms and 11 or 
higher indicating probable presence of the respective state (155). 
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 After diagnosis, patients were divided into two groups: 
• SLE patients with depression (HADS ≥ 8) and without 
depression (HADS < 8); 
•  SLE patients with CNS involvement (Neurolupus) and no 
CNS involvement (without Neurolupus). 
 
3.2. Methods 
 
3.2.1. Biological samples 
 
 Blood, particularly human leukocytes, is usually used from DNA extraction, as 
provides fresh material for analysis (156). DNA was extracted from peripheral blood, 
collected in 4.5 mL in 5 mL collection tubes with 5% EDTA. 
 
3.2.1.1. DNA extraction  
 
 For DNA extraction the salting out procedure was used. This method involves 
salting out of the cellular proteins by dehydration and precipitation with saturated NaCl 
solution. The centrifugation of each EDTA blood collection tubes occurred at 490 g, for 10 
minutes, in the centrifuge Rotofix 32A (Hettich Zentifugen). After centrifugation three 
layers were obtained: plasma, leukocytes ring and erythrocytes. The leukocytes ring was 
removed with a sterile and disposable Pasteur pipette to a 50 mL Falcon tube. 
Lymphocytes were separated from whole blood by the lysis of red blood cells through 
addition up to 50 mL of RCLB (Red Cell Lysis Buffer) to Falcon tube. The RCLB (1 mM 
tris- HCl pH 7.2, 5 M NaCl and 1 M MgCl2.6H2O) was mixed by inverting thoroughly for 5 
minutes and centrifuged (Heraeus Megafuge 16R–Thermo Scientific) at 828 g, at 4°C for 
10 minutes. The supernatant was discarded, the pellet was resuspended and RCLB was 
added and centrifuged at the same conditions. Addition of RCLB and centrifugation steps 
was repeated two to three times until a clean white pellet of leucocytes was obtained. 
After the final wash, the supernatant was discarded completely and 3.5 mL of TE2 (10 mM 
Tris- HCl pH 7.2, 0.4 M NaCl and 2 mM EDTA) were added; 200 µL of 10% SDS (Sodium 
Dodecyl Sulfate) and 10 µL of proteinase K (50 mg/mL) were added to promote the lysis 
of leukocyte membranes and digest the proteins bound to DNA, respectively. The sample 
was incubated for 12 hours at 42ºC in a water bath. Thereafter the solution was 
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transferred into a 15 mL Falcon tube. For the precipitation of proteins 1 mL of 6 M NaCl 
was added leaving under stirring for 10 minutes. The tube was centrifuged at 1923 g at 
room temperature for 30 minutes and the DNA was obtained in the supernatant and 
proteins in the sediment portion which accumulate after centrifugation. The supernatant 
was transferred to a 50 mL tube and was added cold absolute ethanol to make up 25 mL. 
The ethanol promoted the DNA precipitation in the solution. The supernatant was 
discarded and the pellet was washed with cold 70% ethanol. The pellet was air-dried in 
the tube wall and subsequently transferred into a 1.5 mL eppendorf containing 500 µL of 
TE buffer (10 mM Tris-HCl pH 7.2 and 1 mM EDTA). The DNA solution was ready for use 
after overnight shaking in the rotary shaker (Stuart Scientific - Blood tube rotator SB1). 
 
3.2.1.2. DNA quantification 
 
 DNA was quantified by measuring the absorbance at 260 nm in a NanoDrop ND 
-1000 spectrophotometer v3.6.0 (Thermo Scientific). To evaluate the presence of potential 
contaminants measurement at wavelength 280 nm (proteins) and 230 nm (organic salts) 
was undertaken. This measurement is important since the absorbance ratios 260/280 and 
260/230, which should be between 1.8 to 2.0 and 1.5 to 2.0 respectively provide 
information about the purity of DNA. 
 
3.2.2. Genetic studies 
 
3.2.2.1. Genetic association studies 
  
 In order to identify candidate genes, these studies test for an association 
between disease status and genetic variations. The test makes a comparison between the 
patients with the disease and the control population without the disease. A higher 
frequency of an allele or genotype in individuals affected with a disease suggests that the 
tested variant increases the risk of the specific disease. Likewise, a lower frequency in 
patients indicates a possible protective role in the disease. 
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3.2.2.2. Genetic variations 
 
 Polymorphisms are variations in the DNA sequence. The SNP represents a 
difference in a single DNA nucleotide and is the most common type of genetic variation 
among people. While not as common as SNPs, VNTRs and insertion/deletion 
polymorphism are widely spread across the genome. VNTRs are linear arrangement of 
multiple copies of short repeated DNA sequences that vary in length and are highly 
polymorphic.  An insertion/deletion polymorphism is a type of genetic variation in which a 
specific nucleotide sequence is present (insertion) or absent (deletion).  
 
 This project focused in polymorphisms that may affect the function and/or 
expression of proteins relevant to the serotonergic system. 
 
3.2.3. Applied techniques 
 
3.2.3.1. PCR 
 
 For the genotyping of different polymorphisms, techniques based on the 
polymerase chain reaction (PCR) were used. 
 
 In 1993 the Nobel Prize for Chemistry Kary Mullis developed the PCR, a 
methodology that consists in the exponential amplification of a specific DNA sequence 
from a reduced amount. Based on the replication of cells in vivo, the principle of PCR 
involves the enzymatic amplification of a template DNA fragment delimited by two primers.  
This technique needs several components: 
 
• DNA template containing the sequence to be amplified; 
• Primers, oligonucleotides that define the region to be amplified; 
• dNTP 's (deoxynucleotide triphosphates) for the construction of the new chain of 
DNA; 
• DNA polymerase, the enzyme that catalyzes the reaction addition of dNTP 's; 
• The Mg2 + ion, the enzyme cofactor; 
• Buffer solution that maintains the appropriate conditions for the activity of the 
enzyme. 
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 The PCR technique comprises three steps: denaturation of DNA, binding 
(annealing) of the primers and extension of the DNA chain. These steps together are 
referred to as a cycle and are repeated a number (30-40 usually) of times (figure 10). 
 
 
 In denaturation, the higher temperature (92-95°C) separates the double-
stranded template DNA. Binding of the primers to the complementary DNA sequences 
then occur. The required temperature is between 50°C and 65°C depending on the 
primer’s sequence and length. Finally, the temperature is rise to 72°C and the DNA 
polymerase enzyme synthesizes the new chain. The DNA polymerase used is Taq 
polymerase, isolated from the bacterium Thermus aquaticus (Taq), whose main feature is 
stability at higher temperatures. PCR is a highly versatile technique and has been 
modified for various applications (157). 
 
 This method was used to genotype the STin2 polymorphism. PCR was used to 
amplify a specific sequences and its size was determined by gel electrophoresis. 
 
 The sequence of primers is described in table 1. A Mastermix was prepared 
containing the components described in table 2. This mixture was homogenized and 9 µL 
was added to reaction tubes containing 50 ng of DNA (for a final volume of 10 µL). The 
PCR cycles occurred in a TProfessional Thermocycler (Biometra) (table 3). 
 
Table 1 – Sequence of primers used from STin2 analysis. 
Gene Polymorphism Primer sequence 
5-HTT STin2 
Forward 5’-GGT CAG TAT CAC AGG CTG CGA CTA G-3’ 
Reverse 5’-TGT TCC TAG TCT TAC GCC AGT GAA G-3’ 
 
 
Figure 10 – The PCR steps. (Adapted: 
http://microfluidics.stanford.edu/Projects/Current/OnChipPCR.html. Accessed: 23-01-
2015) 
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Table 2 – Components and their respective concentrations for PCR used from STin2 analysis. 
 
Table 3 – Thermic profile used from STin2 analysis. 
 
 
 DNA fragments were separated in an agarose gel 4% (w/v) electrophoresis gel. 
Previously, 1 µL of Loading Buffer was added to samples. The DNA is negatively charged 
due to the presence of phosphate groups when an electrical field is applied, migration 
occurs from the negative to the positive pole. Smaller molecules migrate faster than the 
higher weight molecules, thus the fragments are separated according to their fragment 
size. The fragments are visible in ultraviolet light after staining with ethidium bromide 
(figure 11). 
 Stock 
concentration 
 
Reaction 
concentration 
MgCl2 (Bioline) 50 mM 1,50 mM 
Reaction Buffer (Bioline) 10 x 1 x 
dNTPs mix (Bioron) 25 mM 0,5 mM 
Forward primer 10 µM 0,50 µM 
Reverse primer 10 µM 0,50 µM 
GoTaq G2 Flexi DNA Polymerase 
(Promega, Madison, WI USA) 5 U/µL 0,04 U/µL 
ddH2O (Braun) - 
T (ºC) Time Cycles numbers 
95 3 minutes 1 
94 10 seconds 
35 63 1 minute 
72 1 minute 
72 7 minutes 1 
4  
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3.2.3.2. Real-Time PCR 
 
 Introduced in 1992 by Higuchi and coworkers the real-time PCR is a modification 
of conventional PCR [166]. Real-time PCR allows precise quantification of specific nucleic 
acids even when the starting amount of material has a very low concentration. This is 
accomplished by monitoring the amplification of a short DNA fragment containing the 
polymorphism site and detection, in real time, using fluorescent technology. Fluorescence 
can be detected after amplification using an intercalating dye (ethidium bromide) or during 
amplification using sequence specific fluorescent probes such as Taqman probes. 
 
3.2.3.3. TaqMan technology 
 
 The exonuclease activity of Taq polymerase enzyme is employed to increase the 
specificity of PCR detection. The technique is specific, quantifiable and helpful for 
assaying large numbers of samples (158). A TaqMan probe is a oligonucleotide sequence 
that binds to a specific sequence where a polymorphism is included, allowing detection 
and quantification of fluorescence. For genotyping two TaqMan probes that differ only in 
sequence at the SNP site are used. One of the probes is complementary to the wild-type 
allele and the other for the alternative allele. Also, they exhibit different fluorescence 
colors to enable distinction. These probes have attached two types of fluorophores the 
reporter (at the 5’ end) and the quencher (at the 3’ end). The reporter emits fluorescence 
and the quencher reduces the fluorescence of the first when nearly. 
 
Figure 11 – Genotypes of STin2 obtained by PCR. STin2.12 allele corresponds to 12
repeat units of 17bp; STin2.10 allele corresponds to 10 repeat units of 17bp; STin2.9 
allele corresponds to 9 repeat units of 17bp. 
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 In the PCR annealing step the TaqMan probes hybridize to the targeted SNP site. 
During the extension the DNA polymerase removes nucleotides from the probe, from 5’ to 
3’, and release the reporter and quencher dyes. When the probes are intact, fluorescence 
is suppressed because the quencher dyes are in the proximity of the reporter dyes. 
Separating the reporter from the quencher allows the first to emit fluorescence, making 
possible its detection. This detection is only possible when the probes are perfectly 
hybridized, since DNA polymerase will not recognize a probe containing a mismatched 
base. The fluorescence is detected by PCR equipment with an integrated fluorometer. 
During the experiment, the fluorescent signal for the two reporter dyes is measured (figure 
12). 
 
 This method was applied to study the SNP rs6314 (1354 C>T) in the gene 
encoding the 2A receptor of serotonin. Each assay consisted of a total of 8 µL containing 
12.5 ng of DNA, sterile double-distilled water Braun (Braun), 1x from TaqMan® Gene SNP 
Assay kit (C_11696920_20 TaqMan® Gene SNP Assay kit from Applied Biosystems, 
Foster City, CA, USA) and 1x from TaqMan® Universal PCR MasterMix (Applied 
Biosystems, Foster City, CA, USA). The TaqMan® Gene SNP Assay contain the probes 
and primers and the TaqMan® Universal PCR MasterMix contain DNA polymerase, 
dNTPs, magnesium and buffer solution (table 4). In each protocol three samples with 
known genotype as a comparative term and a negative control (sterile double-distilled 
Figure 12 – RT-PCR steps with Taqman® probes for genotyping. (Adapted: 
http://www.applied-maths.com/applications/taqman-based-snp-genotyping. Accessed: 28-
01-2015)  
Chapter 3 – Materials and Methods  
ICBAS – UP 
 
38 
 
water Braun) were used. The reaction was carried out in a Rotor–GeneTM 6000 series 
thermocycler (Rcorbett) (table 5). 
 
Table 4 – Components and their respective concentrations for PCR used from rs6314 analysis. 
 
Table 5 – Thermic profile used from rs6314 analysis. 
 
 
3.2.3.4. PCR-RFLP 
 
 RFLP (Restriction Fragment Length Polymorphism) is a technique based on 
detection of fragments of different lengths after digestion of the DNA samples with specific 
restriction endonucleases. The enzymes require 4-6 base pair recognition sequences and 
when total DNA is digested a large number of fragments generally result (159). In order to 
study the restriction pattern of DNA, the fragments need to be separated according to size 
and the fragments of interest distinguished from all other similarly sized fragments.  
 
 In PCR-RFLP, digested PCR product is separated by gel electrophoresis (agarose 
or polyacrylamide), and individual fragments are identified (figure 13). 
 Stock 
concentration 
 
Reaction 
concentration 
TaqMan® Universal PCR MasterMix  2 x 1 x 
TaqMan® Gene SNP Assay  40 x 1 x 
DNA 12.5 ng/µL 12.5 ng/8µL 
ddH2O (Braun) - 
T (ºC) Time Cycle numbers 
95 10 minutes 1 
93 15 seconds 
40 58 40 seconds 
72 20 seconds 
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 This method was applied to study the SNP rs6313 (102 T>C) in the gene encoding 
the 2A receptor of serotonin. PCR amplified the specific sequences and their size 
determined by gel electrophoresis, after MSPI digestion.  
 
 The sequence of primers was described in table 6. The Mastermix was prepared 
for a total reaction volume of 20 µL containing the components described in table 7. The 
mixture was homogenized and 19 µL were added to reaction tubes with 50 ng of DNA. 
The PCR program was carried out in GeneAmp® PCR System 2700 (Applied Biosystems) 
(table 8). 
 
Table 6 – Sequence of primers used from rs6313 analysis. 
Gene Polymorphism Primer sequence 
5-HTT rs6313 
Forward 5’-TGA TGA CAC CAG GCT CTA CAG T-3’ 
Reverse 5’-CAG GAA AGG TTG GTT CGA TT-3’ 
 
 
 
Figure 13 – Procedure of PCR-RFLP technique. (Adapted: 
http://answermeup.com/questions/perform-rflp-pcr.html. Accessed: 
27.05.2015) 
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Table 7 – Components and their respective concentrations for PCR used from rs6313 analysis. 
 
Table 8 – Thermic profile used from rs6313 analysis. 
 
 
 After amplification of the sequence containing the polymorphism, the samples 
were subjected to digestion with the Thermo Scientific FastDigest MspI restriction enzyme 
(table 9). The Mix was prepared for a total of 21 µL (table 10) and was added to reaction 
tubes with 10 µL of PCR product.  
 
Table 9 – MspI restriction enzyme cleavage site used from rs6313 analysis. 
MspI restriction enzyme 
 
5’…C   CGG…3’ 
 
3’…GGC   C…5’ 
 
 
 
 Stock 
concentration 
Reaction 
concentration 
MgCl2 (Bioline) 50 mM 2,00 mM 
Reaction Buffer (Bioline) 10 x 1 x 
dNTPs mix (Bioron) 25 mM 0,2 µM 
Forward primer 10 µM 1,00 µM 
Reverse primer 10 µM 1,00 µM 
GoTaq G2 Flexi DNA Polymerase 
(Promega, Madison, WI USA) 5 U/µL 1 U/20µL 
ddH2O (Braun) - 
T (ºC) Time Cycles numbers 
94 3 minutes 1 
94 30 seconds 
35 58 30 seconds 
72 1 minute 
72 3 minutes 1 
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Table 10 – Components and their respective concentrations for digestion protocol used from 
rs6313 analysis. 
 
 After overnight incubation at 37ºC the DNA fragments were separated by an 
electrophoresis gel. Previously was added 1 µL of Loading Buffer to samples and the 
migration occurred in 3% (p/v) NuSieve® agarose gel. After separation, the DNA 
molecules were visualized under ultraviolet light (figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4. Statistical Analysis 
 
 Allele frequencies were compared using the chi-square test or the Fishers exact 
test, as appropriate. For genotype frequencies p values and Odds Ratio (OR) were 
calculated using binary logistic regression. A student’s t-test was used when comparing 
continuous data. 
 
 A multivariable-logistic regression was performed (with the most frequent 
homozygote as the reference category), in order to evaluate the association between the 
 Stock 
concentration 
Reaction 
concentration 
Tango Buffer (Thermo Scientific) 10x 1x 
MSP I enzyme (Thermo Scientific) 10 U/µL 10 U/µL 
H2O - 
Figure 14 – Genotypes of rs6313 obtained from 
PCR-RFLP with the MSPI restriction enzyme. 
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SNPs genotypes and the occurrence of depression in SLE patients, by including the 
studied SNPs in the model and adjusting for patient's age and education. 
 
 The level of significance for comparisons was p<0.05. All analyses were carried 
out with PASW Statistics 20 software. 
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4.1. Studied polymorphisms in SLE patients  
 
 Allele and genotype frequencies from the polymorphisms of the studied genes 
were compared between SLE patients (n= 96) and the control population (n= 274). No 
statistically significant differences were observed in the frequencies of the studied 
polymorphisms between these two groups (tables 11 and 12).  
 
Table 11 – Allelic frequencies in the control population (CP) and SLE patients. 
 
Table 12 – Genotype frequencies in the control population (CP) and SLE patients. 
 Genotype CP (n=274) 
% (n) 
SLE (n=96) 
% (n) 
OR (CI 95%) p 
rs6313 
CC 
CT 
TT 
29.9 (82/274) 
44.2 (121/274) 
25.9 (71/274) 
23.0 (20/87) 
58.6 (51/87) 
18.4 (16/87) 
1 
1.73 (0.96-3.11) 
0.92 (0.44-1.92) 
0.064 
0.068 
0.832 
rs6314 
CC 
CT 
TT 
85.0 (226/266) 
13.9 (37/266) 
1.1 (3/266) 
89.6 (86/96) 
10.4 (10/96) 
0 (0/96) 
1 
0.71 (0.34-1.49) 
- 
0.664 
0.366 
0.999 
Stin2 
12-rpt/10-rpt 
12-rpt/12-rpt 
10-rpt/10-rpt 
42.1 (94/223) 
47.1 (105/223) 
10.8 (24/223) 
54.3 (51/94) 
35.1 (33/94) 
10.6 (10/94) 
1 
0.58 (0.34-0.97) 
0.77 (0.34-1.73) 
0.119 
0.039* 
0.524 
* loses significance with correction for the number of alleles. 
 Allele CP (n=548) 
% (n) 
SLE (n=192) 
% (n) 
OR (CI 95%) P 
rs6313 C 
T 
52.0 (285/548) 
48.0 (263/548) 
52.3 (91/174) 
47.7 (83/174) 
1.01 (0.72-1.42) 0.947 
rs6314 C 
T 
91.9 (489/532) 
8.1 (43/532) 
94.8 (182/192) 
5.2 (10/192) 
1.60 (0.79-3.25) 0.190 
Stin2 12-rpt 
10-rpt 
68.2 (304/446) 
31.8 (142/446) 
62.2 (117/188) 
37.8 (71/188) 
0.77 (0.54-1.10) 0.149 
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4.2. Patients characteristics 
 
 Patient clinical and demographic characteristics are given in table 13. The patient 
population has a mean age of 42.5 years and is predominantly composed of female 
individuals (95.8%). Age and education level were significantly associated with depression 
(p=0.002 and p=0.006, respectively). The diagnosis of depression (HADS≥8) was more 
prevalent among older adults (mean age of 47.5 years). Likewise, depressive symptoms 
are more prevalent in patients with lower education levels (55.3%). The majority of SLE 
patients have education levels equal or greater than 9 years.  
 
Table 13 – Demographic characteristics of SLE patients. 
 a Fisher's Exact Test 
 b T student Test 
c Pearson Chi-Square Test 
 
 
 It is worthy of note that the prevalence of depression is similar in patients with 
and without NPSLE, 39.5% and 36.2% respectively. 
 
4.3. Studied polymorphisms and depression 
 
 In order to understand if the rs6313, rs6314 and Stin2 polymorphisms are 
involved in the development of depression in SLE patients, the allelic and genotypic 
frequencies were analyzed in a cohort of 96 patients subdivided in two categories using 
the depression scale (table 14 and 15). 
 
Total SLE 
(n=96) HADS≥8 (n=38) HADS<8 (n=58) 
p 
 
Gender 
Female, n (%) 
Male, n (%) 
 
92 (95.8) 
4 (4.2) 
 
37 (97.4) 
1 (2.6) 
 
55 (94.8) 
3 (5.2) 
 
1.000a 
Age (mean ± standard deviation) 42.5 ± 13.3 47.5 ± 13.6 39.2 ± 12.2 0.002b 
Education level 
< 9 years 
≥ 9 years 
 
37 (38.5) 
59 (61.5) 
 
21 (55.3) 
17 (44.7) 
 
16 (27.6) 
42 (72.4) 
 
0.006c 
NPSLE 
Yes 
No 
 
36 (37.5) 
63 (62.5) 
 
15 (39.5) 
23 (60.5) 
 
21 (36.2) 
37 (63.8) 
 
0.746c 
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 The rs6313T allele was more frequent among depressive SLE patients 
compared to non-depressive SLE patients (57.1 vs. 41.3, p=0.041, OR [95%CI]=1.891 
[1.02–3.49]). The frequency of the rs6313TT genotype was significantly higher in 
depressive SLE patients when compared to SLE patients without diagnosed depression 
(31.4 vs. 9.60, p=0.027, OR [95%CI]=5.391 [1.22–23.82]). 
 
Table 14 – Allele frequencies in SLE patients with depression (HADS≥8) and without depression 
(HADS<8). 
 
 
Table 15 – Genotype frequencies in SLE patients with depression (HADS≥8) and without 
depression (HADS<8). 
 
 Allele 
HADS≥8 (n=76) 
% (n) 
HADS<8 (n=116) 
% (n) 
OR (CI 95%) P 
rs6313 
C 
T 
42.9 (30/70) 
57.1 (40/70) 
58.7 (61/104) 
41.3 (43/104) 
1.891 (1.02-3.49) 0.041 
rs6314 
C 
T 
94.7 (72/76) 
5.3 (4/76) 
94.8 (110/116) 
5.2 (6/116) 
0.982 (0.27-3.60) 1.000 
Stin2 
10-rpt 
12-rpt 
34.7 (25/72) 
65.3 (47/72) 
39.7 (46/116) 
60.3 (70/116) 
0.809 (0.44-1.49) 0.809 
 
G
e
n
o
ty
p
e
 
HADS≥8 (n=38) 
% (n) 
HADS<8 (n=58) 
% (n) 
OR (CI 95%) P 
rs6313 
CC 
CT 
TT 
17.1 (6/35) 
51.4 (18/35) 
31.4 (11/35) 
26.9 (14/52) 
63.5 (33/52) 
9.60 (5/52) 
1 
1.27 (0.42-3.88) 
5.13 (1.23-21.3) 
0.045 
0.672 
0.025 
rs6314 
CC 
CT 
89.5 (34/38) 
10.5 (4/38) 
89.7 (52/58) 
10.3 (6/58) 
1.02 (0.27-3.88) 1.000 
Stin2 
12-rpt/10-rpt 
12-rpt/12-rpt 
10-rpt/10-rpt 
47.2 (17/36) 
41.7 (15/36) 
11.1 (4/36) 
58.6 (34/58) 
31.0 (18/58) 
10.3 (6/58) 
1 
1.67 (0.68-4.10) 
1.33 (0.33-5.37) 
0.535 
0.265 
0.686 
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 As the age and education level presented significant differences in depressed 
patients (table 13) it was important to take into account these demographic 
characteristics. Logistic regression modelling confirmed the reported association 
independently from age and education level (p = 0.027, OR [95%CI] = 5.391 [1.22 - 
23.82]). 
 
4.4. Studied polymorphisms and NPSLE 
 
 The allelic and genotypic frequencies of the studied polymorphisms were also 
compared between patients with (n=36) and without (n=60) neuropsychiatric symptoms 
(NPSLE). The frequencies of the studied polymorphisms were similar in the two groups 
(table 16 and 17). 
 
Table 16 – Allelic frequencies in SLE patients with and without NPSLE 
 
 
 
 
 
 
 Allele 
NPSLE (n=72) 
% (n) 
Non-NPSLE (n=120) 
% (n) 
OR (CI 95%) P 
rs6313 
C 
T 
57.8 (37/64) 
42.2 (27/64) 
49.1 (54/110) 
50.9 (56/110) 
0.704 (0.38-1.31) 0.267 
rs6314 
C 
T 
95.8 (69/72) 
4.2 (3/72) 
94.2 (113/120) 
5.8 (7/120) 
1.42 (0.36-5.69) 0.746 
Stin2 
10-rpt 
12-rpt 
34.3 (24/70) 
65.7 (46/70) 
39.8 (47/118) 
60.2 (71/118) 
0.788 (0.43-1.46) 0.448 
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Table 17 – Genotype frequencies in SLE patients with NPSLE and with non-NPSLE. 
 
 
 
G
e
n
o
ty
p
e
 
NPSLE (n=36) 
% (n) 
Non-NPSLE (n=60) 
% (n) 
OR (CI 95%) P 
rs6313 
CC 
CT 
TT 
31.3 (10/32) 
53.1 (17/32) 
15.6 (5/32) 
18.2 (10/55) 
61.8 (34/55) 
20.0 (11/55) 
1 
0.50 (0.17-1.43) 
0.45 (0.11-1.79) 
0.380 
0.197 
0.260 
rs6314 
CC 
CT 
91.7 (33/36) 
8.3 (3/36) 
88.3 (53/60) 
11.7 (7/60) 
0.69 (0.17-2.85) 0.739 
Stin2 
12-rpt/10-rpt 
12-rpt/12-rpt 
10-rpt/10-rpt 
62.9 (22/35) 
34.3 (12/35) 
2.8 (1/35) 
49.2 (29/59) 
35.6 (21/59) 
15.3 (9/59) 
1 
0.75 (0.31-1.85) 
0.15 (0.02-1.24) 
0.200 
0.537 
0.078 
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5.1. Discussion 
 
5.1.1. Role of studied polymorphisms in SLE patients  
 
 A possible relationship between serotonergic pathways and SLE has been 
suggested. Autoimmune diseases, including SLE, may result from disruption of 
homeostasis in neurological, immune and endocrine systems. Hereupon some authors 
have claimed that the serotonergic system plays an important role in this network of 
neurotransmitters, cytokines and endocrine glands hormones (160). Meyerhoff et al have 
observed significantly lower serotonin levels in 41 SLE patients, and the lowest levels 
occurred in patients with active disease (161). In addition, another study found 
overexpression of serotonin receptor type 3A (5-HTR3A) in peripheral blood cells of SLE 
patients compared to healthy individuals (160). Several polymorphisms such as rs6313, 
rs6314 and STin2 may influence the function of the serotonin receptor and transporter. In 
fact, there are some studies that report association between polymorphisms in 
serotonergic system and SLE: Birmingham et al reported that the 1019C>G polymorphism 
in the 5-HTR1A gene is related to fluctuation in self-perceived stress, which in turn leads 
to the onset of flare in SLE patients (162). A previous small-scale study has reported an 
association between the 5-HTR2A rs6311A allele and SLE development in a Portuguese 
population (163). To the best of our knowledge, no previous documented studies exist 
assessing the rs6313, rs6314 and STin2 serotonergic system polymorphisms in SLE.  
 
 Our results do not show an influence of these polymorphisms in SLE susceptibility, 
however it is possible that the homeostasis of the serotonergic system could be influenced 
by other polymorphisms in the same pathway. Additional research is needed, including, 
for instance, of the 5-HTTLPR polymorphism. Studies in larger populations are also 
needed.  
 
 It is known that SLE patients have a greater vulnerability or predisposition to 
depressive symptoms (164). In fact, it has been reported that depression affects around 
17-75% of SLE patients (34). The notion that depression represents a manifestation of 
SLE is controversial. Nevertheless, it has been concluded that depression is more 
common among SLE patients that in a similar group of rheumatoid arthritis patients (165).  
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 Tissue inflammation in SLE might be the link to serotonergic abnormalities in 
depression. Also, in addition to the general effects of chronic disease, it has been reported 
that depressed SLE patients have greater cognitive deficits (learning and attentional skills) 
when compared to depressed controls and healthy control subjects (164). However, the 
etiology of depression in SLE remains controversial. There is some discrepancy in the 
literature regarding the association between psychological characteristics and SLE. Some 
studies have shown a relationship between cognitive and psychological status and 
depression in non-NPSLE. Nevertheless no significant differences were found in global 
cognitive impairment between non-NPSLE patients and healthy controls (164) (166). 
Thus, it is still not known if depression is associated with the effects of a chronic illness or 
if it represents a manifestation of CNS involvement in these patients. 
 
 Depression in our SLE cohort is more prevalent in women (n=37; 40%)) and older 
adults (47.5 ± 13.6), in agreement with previous reports. Patients with lower education 
levels (n=21; 57%) are also more prone to depression. A recent systematic review, 
reported that depression was the most common psychiatric comorbidity (18-75%) in SLE 
patients, particularly in females (87–100%) (167). It is known that depression is also more 
prevalent in women with no underlying disease (45) (46) (168). Some authors suggest 
that the higher prevalence of depression in women can be due to biological reasons such 
as hormonal factors at the onset of puberty (47), and/or social factors such as poor social 
relationships (168). An Iranian study found that 45.5% of depressive SLE patients had 
more than 35 years of age (169). This suggests a shift in depression patterns with aging. 
It is likely that older adults may suffer from aggravating psychosocial conditions such as 
isolation, marital separation, grief and economic impoverishment. Suicide in older adults is 
also more likely to be preceded by depression compared to suicide at any other age 
(170). Education levels, as well as socioeconomic factors, have a strong linkage to 
depression. This may be due to the relation between lower education level and low 
socioeconomic status. This means that living conditions, environmental stressors and 
perhaps even impaired cognitive functioning are important in the onset of depression 
(168). 
 
 It is important to note that factors leading to depression in SLE patients include the 
social consequences and patients’ responses to the burden of the disease. An American 
study compared the quality of life in SLE patients with the quality of life in other chronic 
illnesses (hypertension, congestive heart failure, adult onset diabetes mellitus, myocardial 
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infarction and depression). The quality of life of SLE patients was significantly worse and 
affected all health domains at an earlier age compared to other chronic diseases (171). 
This finding supports the relevance of the present work and the need of future studies to 
elucidate the underlying processes of depression and its relationship with SLE. 
 
5.1.2. Role of studied polymorphisms in depression 
 
 Depression is an important public health problem due to its devastating 
consequences. It is associated with an increased risk of suicide and decreased physical, 
cognitive and social functioning, with greater self-neglect, leading to an increased risk of 
mortality. Therefore recognition of depression, a treatable condition, is of utmost 
importance. 
 
 Published research provides examples of polymorphisms that may contribute to 
the risk of depression. Our results showed that the rs6313T allele of the 5-HTR2A gene 
was associated with depression susceptibility in SLE patients. Likewise, the TT genotype 
also shows association with depression in our patients. This association was already 
reported in a smaller SLE Portuguese population (172). Located on exon 1 of the 5-
HTR2A gene, the rs6313 polymorphism probably interferes with receptor activity. Khait et 
al reported that the TT genotype is associated with a higher 5-HTR2A density in platelet in 
both mood disorders and in the healthy population (173). Platelets are a source of 5-
HTR2A with similar characteristics to the brain receptors. This greater 5-HTR2A platelet 
binding was proposed to be associated with impairment of serotonin neurotransmission, 
and a likely cause of depressive symptoms (173). The rs6313 polymorphism is in 
complete linkage disequilibrium with rs6311, located in the promoter region of the 5-
HTR2A gene. There is evidence that the rs6311 polymorphism results in inadequate 
promoter activity, with lower transcription of the gene (174). Thus, the rs6311 may also 
play an important role in this setting.  
 
 Our results are not in agreement with those reported for different populations. In 
general, the rs6313C allele has been associated with depression (85) (87) (175) (176). 
This allele has also been associated with suicide in depressed patients (175) and a more 
frequent CC genotype was found in alcohol-dependent females (87).  
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 Contradictory results are a very common phenomena in studies of complex 
diseases, that arise from the interaction of several genes with additional environmental 
factors. One reason is the differences observed in allele prevalence, characteristic of the 
studied population. Allele frequencies in our study are very different from the frequencies 
previously reported for depressed patients in other populations (table 18). 
 
Table 18 – Allelic frequencies of rs6313 in depressed patients. 
Study Year Patients Nationality 
C allele frequency 
(%) 
T allele frequency 
(%) 
This study 2015 Portuguese 43 57 
Petit A.-C. et al 2014 French 56 44 
Wrzosek M. et al 2011 Polish 68 32 
Arias B. et al 2001 Spanish 53 47 
Zhang H.-Y. et al 1997 Japanese 59 41 
 
 
 Discrepancies between studies may also be due to differences in phenotype 
definition (study heterogeneity). Unlike in our study, the other studies have been 
conducted in subjects with depression and psychological disorders with no other 
underlying medical conditions. In SLE patient’s depression may develop by different 
mechanisms.  An interesting study, reported that the rs6313T allele and TT genotype 
were associated with increased depressive symptoms in subjects who live in remote rural 
areas. Surprisingly, the CC genotype was associated with increased depressive 
symptoms in urban residents. These results suggest that different mechanisms may be 
involved in the development of depression depending on the nature of the  environmental 
influences (177). Following this line of reasoning, SLE may function as a life experience 
that leads to a higher vulnerability to depression in the rs6313T allele carriers.  
 
 Other studies, as well as a recent meta-analysis, found no significant involvement 
of the rs6313 polymorphism in depression (178) (179) (180). Both original studies had a 
large number of patients, 325 and 420, and a total of 21 studies were included in the 
meta-analysis. Although our results are based in a lower number of patients, they can be 
considered an interesting exploratory finding that needs replication in other SLE 
populations. 
 
 No significant association between rs6314 alleles and depression in SLE patients 
was found. These results are in agreement with those of a study with 684 elderly Danish 
twins (181). Another study with 485 European descent individuals identified two that 
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carried the rare rs6314TT genotype and presented a more severe depressive episode 
(85). The authors suggested that the TT genotype has reduced ability to activate G 
proteins downstream of 5-HTR2A, causing decreased 5-HTR2A-mediated intracellular 
signaling (85). We have not found any patient with this rare genotype. 
 
 The 5-HTT STin2.12 (12 repeat) allele has been associated with increased gene 
transcription, that may decrease serotonin availability when compared to the STin2.10 
allele (91). Some studies have found no association between the STin2 polymorphism 
and depression in an elderly population (181), or with suicidal ideation in depressive 
patients (179). However, Pizzo de Castro et al showed that patients with both tobacco use 
disorder and mood disorders (depression or bipolar disorder) have a significant increased 
frequency of the STin2.12 allele and a lowered frequency of the STin2.10/10 genotype 
(96). Another study suggested that the presence of STin2.10 allele and the absence of 
STin2.12 allele might be related to the characteristic cognitive dysfunction of depressive 
patients (92). In the present study no association was found between serotonin 
transporter polymorphisms and depressive symptoms. Our sample size may have had 
insufficient power to detect the contribution of this gene variation to a complex disease 
such as depression. Also, it is possible that this putative contribution depends on epistatic 
interaction between 5-HTTLPR and STin2 defining the transcription level of the 5-HTT 
gene. Furthermore, some authors have suggested that the role of serotonin transporter 
polymorphisms in gene function could be more complex than generally assumed (181). 
 
5.1.3. Role of studied polymorphisms in NPSLE  
 
 The expression patterns of the 5-HTR2A and 5-HTT in the brain, have been 
implicated not only in various central physiological functions including memory, sleep, 
eating and reward behaviors, but also in many neuropsychiatric disorders.  
 
 We found no statistically significant associations between the studied 
polymorphisms and NPSLE. A previous study found no differences between depression 
frequencies in patients with and without NPSLE (182). We had too few patients to 
replicate this observation. 
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5.2. Conclusions 
 
 The neurobiology of depression has been widely studied over the years. The 
monoamine hypothesis was the first theory to explain the etiology of the disease. 
Nowadays others theories have emerged and it is useful to further explore the theme. A 
substantial proportion of genetic risk factors for depression appear to be shared in men 
and women. Several studies have tried to associate polymorphisms in serotonergic 
system genes with psychiatric disorders. Also other works have referred the higher 
prevalence of depressive symptoms in SLE patients. So the identification of 
polymorphisms in the serotonergic system may facilitate a further step in the 
comprehension of complex topic that is the etiology of depression. Since these genetic 
variations appear to be associated with the different responses to drugs, these studies 
may also have an important role in the development of new therapeutic strategies.  
 
 In this study, some results are controversial compared to other findings reported in 
the literature. This may be due to the complex traits involved, which link depressive 
patients with an underlying autoimmune disease. No relationship was observed between 
the studied polymorphisms and SLE. Lupus is a multifaceted polygenic disease what 
means that it is caused by the combined effect of more than one gene. Consequently, the 
contribution of a single allele or SNP may be greatly reduced making it difficult to detect 
their effect. The rs6313T allele and rs6313TT genotype may be associated with 
depression in SLE patients in the studied population. Thus, our results reinforce the 
existence of a relationship between serotonergic system and depression.  
 
 The exposure to stressful events of life might have a possible epigenetic influence 
in genes responsible for depression, suggesting an area of interest to be taken into 
account in future researches. Other areas of study may include the evaluation of the 
quality of life and the presence of stressful life events and the SLE activity.  
 
Medico-legal aspects are also interested due to the strong physical, psychological 
and social impairment in subjects with SLE. The increased knowledge of brain functions 
opens the opportunity to produce evidence in cases in which disorders of the brain such 
as depression are implicated.  Indeed, the mental condition of an accused person is 
frequently a matter for special consideration in a criminal trial. As well as others 
depressed individuals, depressed SLE patients are also predisposed to commit suicide. 
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Concerns arise related to the prevention of suicide in depressed patients, including 
hospitalization and the appropriated treatment, are of medico-legal importance. 
 
 The present study has some limitations since it is a preliminary study. 
Accordingly, a larger number of patients should be study to validate the association of the 
studied polymorphisms with depression development in SLE patients. There are some 
studies in the literature, reporting the involvement of serotonergic polymorphisms in 
depressive patients. However, to the best of our knowledge, this is the first SLE 
population where these polymorphisms were studied.  
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